Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma.
Journal: Transplantation and cellular therapy
Published: February 05, 2026
Association between exercise and clinical outcomes in patients treated with immunotherapy for solid tumors.
Journal: Frontiers in immunology
Published: August 27, 2025
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
Journal: Pigment cell & melanoma research
Published: October 22, 2022
Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment.
Journal: The oncologist
Published: March 18, 2022
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Journal: Frontiers in immunology
Published: November 06, 2021
Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.
Journal: Pigment cell & melanoma research
Published: February 13, 2020
Impact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma.
Journal: The Journal of surgical research
Published: February 22, 2019
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
Journal: Nature medicine
Published: February 06, 2018
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.
Journal: JCI insight
Published: March 14, 2017
Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Journal: Cancer journal (Sudbury, Mass.)
Published: January 24, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Journal: Cancer immunology research
Published: December 05, 2016
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
Journal: British journal of cancer
Published: October 19, 2016
Last Updated: 09/26/2026